Creating bone tissue from a patient's mesenchymal stem cells in vitro for use in bone grafts.
EpiBone, Inc. is privately-held clinical-stage regenerative medicine company focused on skeletal reconstruction. Sitting at the intersection of biology and engineering, the company harnesses the power of cells to create living solutions that can become a seamless part of a patient’s body. EpiBone is currently developing a pipeline of bone, cartilage, and compound (bone and cartilage) products.
Press Mentions

July 24, 2023
EpiBone to Start Clinical Trials for Knee Cartilage Grown in Lab
/PRNewswire/ -- EpiBone has received Investigational New Drug (IND) clearance from the FDA to begin testing its lab-grown knee cartilage in humans. The...
Read on PRNewswire »
March 9, 2023
EpiBone, emerging biotech company, is relocating to Jersey City — and bringing nearly 100 jobs | ROI-NJ
EpiBone, an emerging biotechnology company co-founded and run by Nina Marie Tandon, is coming to Jersey City after the Board of the New Jersey Economic Development Authority (NJEDA) approved up to...
Read on ROI-NJ »
October 17, 2015
Why Peter Thiel Invested In New York Biotech Startup EpiBone
EpiBone uses stem cells to regrow damaged bones. After getting a PhD from Columbia, Nina Tandon returned to school for an MBA to form a company at the forefront of 'biology as design.'
Read on Inc.com »More Ventures in Health
Get the Unreasonable Newsletter
Get monthly updates on EpiBone and over 370 other ventures working to solve the world's toughest problems.